Literature DB >> 17931444

Hypopharyngeal cancer treatment based on definitive radiotherapy: who is suitable for laryngeal preservation?

S-W Chen1, M-H Tsai, S-N Yang, J-A Liang, A-C Shiau, F-J Lin.   

Abstract

AIMS: To investigate prognostic factors for survival and locoregional control in patients with stage I-IVA hypopharyngeal cancer treated with laryngeal preservation radiotherapy.
METHODS: This study was a retrospective analysis of 108 patients with stage I-IVA squamous cell carcinoma of the hypopharynx, treated with laryngeal preservation radiotherapy. Actuarial survival, disease-specific survival and local relapse-free survival were calculated, and multivariate analyses were performed using Cox's proportional hazards model.
RESULTS: After a median follow-up duration of 39 months, the five-year local relapse-free survival rate was 35 per cent for all patients, 66 per cent for those with stage I-II disease, 46 per cent for those with stage III disease and 20 per cent for those with stage IVA disease (p = 0.004). Multivariate analyses showed that tumour and node stages were independent prognostic factors.
CONCLUSIONS: Patients with stage I-II disease were suitable for laryngeal preservation radiotherapy. For most patients with stage III-IVA disease, other than those who were T1 N1 or T2 N1, the treatment results were poor.

Entities:  

Mesh:

Year:  2007        PMID: 17931444     DOI: 10.1017/S0022215107000692

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Transoral resection of laryngeal and hypopharyngeal cancers.

Authors:  Sultan Pradhan; Marzi Mehta; Arsheed Hakeem; Jagadish Tubachi; R Kannan
Journal:  Indian J Surg Oncol       Date:  2010-11-21

2.  Functional organ preservation in laryngeal and hypopharyngeal cancer.

Authors:  Petra Ambrosch; Asita Fazel
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-04-26

3.  Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer.

Authors:  Jun Won Kim; Mi Sun Kim; Se-Heon Kim; Joo Hang Kim; Chang Geol Lee; Gwi Eon Kim; Ki Chang Keum
Journal:  Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.679

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.